RANBAXY TO DECOMMISSION GLOVERSVILLE, NY FACILITY

RANBAXY TO DECOMMISSION GLOVERSVILLE, NY FACILITY

Princeton, NJ - July 1, 2011 -- Ohm Laboratories Inc (Ohm), a wholly owned subsidiary of Ranbaxy Laboratories Limited (RLL), announced today that it is in the process of decommissioning its liquid manufacturing facility located in Gloversville, New York to focus the Company's resources on other US-based facilities. It is expected that this process will be completed by October 1, 2011 after which the plant will no longer be operational.

The Gloversville facility was acquired by Ranbaxy on July 23, 2002. To date the focus has been in the manufacture of liquid pharmaceutical formulations. The Gloversville, NY facility is one of the three US-based manufacturing sites.

Ohm, based in North Brunswick, New Jersey, is a wholly owned subsidiary of RLL, India's largest pharmaceutical company. Ohm is engaged in the manufacturing of generic, branded and OTC products, as well as in the sale and distribution of private label OTC products in the U.S. healthcare system.

Ranbaxy Laboratories Limited, headquartered in India, is an integrated, research based, international pharmaceutical company producing a wide range of quality, affordable generic medicines, trusted by healthcare professionals and patients across geographies. The Company is serving its customers in over 125 countries and has an expanding international portfolio of affiliates, joint ventures and alliances, ground operations in 46 countries and manufacturing operations in 7 countries. Ranbaxy is a member of the Daiichi Sankyo Group. Daiichi Sankyo is a leading global pharma innovator, headquartered in Tokyo, Japan.

 


 
 
 
 

Media Contacts

Charles M. Caprariello
Vice President, Corporate Communications
Ranbaxy Inc.
(609) 720-5615

Robert Ferris
RF Binder Partners Inc.
(212) 994-7505

Della Burns
RF Binder Partners Inc.
(847) 318-0606

 

Suggested Articles

A suspected cancer-causing impurity that has been found in some blood pressure medicines has now shown up in Zantac and some OTC antacids.

Roche is steamrolling with Ocrevus, and to maintain that lead, its touting long-term data that show the earlier it’s given, the better patients do.

New data shows a significant reduction in relapse rates in patients taking Novartis' repurposed cancer drug ofatumumab.